An open-label, phase I study to determine the safety and pharmacokinetics of JNJ-26483327, a multi-targeted kinase inhibitor, administered to subjects with advanced stage and/or refractory solid malignancies.

Trial Profile

An open-label, phase I study to determine the safety and pharmacokinetics of JNJ-26483327, a multi-targeted kinase inhibitor, administered to subjects with advanced stage and/or refractory solid malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2010

At a glance

  • Drugs JNJ 26483327 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Apr 2010 Actual patient number (19) added as reported by ClinicalTrials.gov.
    • 21 Aug 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 21 Aug 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top